Fourth-quarter revenues decreased to $2.28 billion from $2.46 billion in the corresponding quarter last year. For fiscal 2026, the company expects total revenue to decline by a mid-single digit percentage, versus FY25.
Adjusted earnings, excluding special items, decreased 42% to $1.99 per share in the fourth quarter from $3.44 per share in the year-ago period. The company said it expects full-year 2026 adjusted earnings per share to be between $15.25 and $16.25.
On a reported basis, Biogen posted a net loss of $48.9 million or $0.33 per share for the December quarter, compared to a profit of $266.8 million or $1.83 per share in Q4 2024.
“Going into 2026, we are looking forward to data from two Phase 3 studies in lupus for litifilimab, with 10 additional potentially registrational studies across our pipeline expected to read out sequentially over the next four years. This multi-year registrational data flow has the potential to drive meaningful innovation for patients and long-term value for shareholders,” said Biogen’s CEO Christopher Viehbacher.